Skip to main content
. 2020 Dec;11(6):1350–1363. doi: 10.21037/jgo-20-509

Figure 2.

Figure 2

cfDNA concentration and integrity in healthy people and PHC patients. *P<0.05 vs. control group; #P<0.05, compared with value before TACE treatment. cfDNA, cell-free DNA; PHC, primary hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization.